Dr Goldberg on Investigational Agents in EGFR-mutant NSCLC
Sarah Goldberg, MD, MPH, associate professor, internal medicine (medical oncology), associate director, Medical Oncology-Hematology Program, research director, Center for Thoracic Cancers, chief, Thoracic Oncology, Yale School of Medicine, discusses ongoing investigations with antibody-drug conjugates (ADCs) and bispecific antibodies in patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations.Source: OncLive
Various Cancer Treatment Drugs Experiencing Nationwide Shortage
Dr. Daniel Petrylak, chief of genitourinary oncology at Yale Cancer Center, said some patients have had to switch between certain cancer-treating drugs while waiting for a new supply to come in. “We’re making every effort to give our patients the best possible care, but we hope in the future that this is not going to be more of a magnified problem. We have to start thinking and planning ahead as to how we can alleviate this drug crisis," Petrylak said.Source: NBC 30
Yale researchers say customized cancer vaccine shows promise
A team of researchers at Yale Cancer Center are participating in a Moderna clinical trial that combines an immunotherapy drug known as Keytruda or Pembrolizumab with a customized vaccine created with mRNA technology compared to Keytruda alone. Dr. Thuy Tran and a team of researchers at Yale are studying the treatment in patients who have Melanoma and are at high risk for reoccurrence.Source: Fox 61
Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.
I’m a Breast Cancer Surgeon. Here’s What I Think of the New Screening Guidelines.
When I learned that the U.S. Preventive Services Task Force once again changed its recommendation for when women should begin screening for breast cancer — this time recommending women start at age 40 rather than 50 — I had just finished operating on a 48-year-old African American woman with aggressive breast cancer. My patient had presented to doctors with a painful lump. She didn’t think she needed a mammogram for another two years.Source: The New York Times
CT researchers: Vaccine to fight cancer shows promise using same mRNA technology as COVID drug
The same technology that was used to create Moderna’s COVID-19 vaccine is being targeted on melanoma, and the treatment is having positive effects, according to researchers at the Yale Cancer Center. It’s another step in using the body’s immune system to fight diseases, using a person’s own mRNA to target cancer. The randomized Phase 2 study compares personalized mRNA vaccines given along with Keytruda, an immunotherapy drug with the generic name pembrolizumab, vs. giving Keytruda alone.Source: The Hartford Courant
AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC
Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy alone, according to an interim analysis of event-free survival and a final analysis of pathologic complete response in the phase III AEGEAN trial reported at the American Association for Cancer Research (AACR) 2023 Annual Meeting.Source: ASCO Post
The Caris Precision Oncology Alliance Welcomes Yale Cancer Center
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Yale Cancer Center has joined the Caris Precision Oncology Alliance™ (POA).Source: Caris Life Sciences
New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer
A new phase III study has demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer whose cancers were resistant to previous treatment with trastuzumab emtansine. Both trastuzumab deruxtecan and trastuzumab emtansine are antibody-drug conjugates, a relatively new type of drug that delivers chemotherapy directly to the cancer cell, minimizing damage to normal tissues. The study was published in The Lancet on April 19, 2023.